-

British American Tobacco P.L.C. (BTI) Investor Alert: Robbins LLP Reminds Investors of Class Action Against British American Tobacco P.L.C.

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP reminds investors that a shareholder filed a class action on behalf of all persons and entities that purchased or otherwise acquired British American Tobacco P.L.C. (NYSE: BTI) securities between February 9, 2023 and December 6, 2023. British American Tobacco is a multi-national tobacco company that sells cigarettes (which the Company refers to in its filings as “combustibles” or “sticks”, for individual cigarettes) and other tobacco-related products, such as vaping products, chewing tobacco, snus, and heated tobacco products.

For more information, submit a form, email Aaron Dumas, Jr., or give us a call at (800) 350-6003.

What is this Case About: American British Tobacco P.L.C. (BTI) Failed to Disclose the Risks and Potential Likelihood of an Impairment to its Premium American Cigarette Brands

According to the complaint, during the class period, defendants failed to disclose that British American Tobacco materially understated the risks and potential likelihood of an impairment to its Premium American Cigarette Brands as a result of various longstanding headwinds.

In January 2017, British American Tobacco, which already had a 42% stake in Reynolds American Inc. (“Reynolds”), took over the remaining interest in Reynolds for $49.4 billion dollars, valuing Reynolds at around $86 billion. Reynolds became a subsidiary and British American Tobacco took control of the Camel, Newport, and Natural American Spirit cigarette brands ("Premium American Cigarette Brands"), among others.

On December 6, 2023, British American Tobacco issued a press release announcing that it was taking a 25 billion Pound (or around $31.5 billion USD) impairment on the cigarette brands it acquired from Reynolds. On this news, British American’s ADR price fell $2.68 per share, or 8.88%, to close at $28.86 per ADR on December 6, 2023.

What Now: Similarly situated shareholders may be eligible to participate in the class action against British American Tobacco P.L.C. Shareholders who want to act as lead plaintiff for the class should contact Robbins LLP. Plaintiffs must file their lead plaintiff papers by March 25, 2024. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. You do not have to participate in the case to be eligible for a recovery. If you choose to take no action, you can remain an absent class member. For more information, click here.

All representation is on a contingency fee basis. Shareholders pay no fees or expenses.

About Robbins LLP: Some law firms issuing releases about this matter do not actually litigate securities class actions; Robbins LLP does. A recognized leader in shareholder rights litigation, the attorneys and staff of Robbins LLP have been dedicated to helping shareholders recover losses, improve corporate governance structures, and hold company executives accountable for their wrongdoing since 2002. Since our inception, we have obtained over $1 billion for shareholders.

To be notified if a class action against British American Tobacco, P.L.C. settles or to receive free alerts when corporate executives engage in wrongdoing, sign up for Stock Watch today.

Attorney Advertising. Past results do not guarantee a similar outcome.

Contacts

Aaron Dumas, Jr.
Robbins LLP
5060 Shoreham Pl., Ste. 300
San Diego, CA 92122
adumas@robbinsllp.com
(800) 350-6003
www.robbinsllp.com

Robbins LLP

NYSE:BTI

Release Summary
American British Tobacco P.L.C. (BTI) Failed to Disclose the Risks and Potential Likelihood of an Impairment to its Premium American Cigarette Brands
Release Versions
$Cashtags

Contacts

Aaron Dumas, Jr.
Robbins LLP
5060 Shoreham Pl., Ste. 300
San Diego, CA 92122
adumas@robbinsllp.com
(800) 350-6003
www.robbinsllp.com

Social Media Profiles
More News From Robbins LLP

Investor Notice: Robbins LLP Informs Investors of the Vistagen Therapeutics, Inc. Securities Class Action

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP informs investors that a class action was filed on behalf of all investors who purchased or otherwise acquired Vistagen Therapeutics, Inc. (NASDAQ: VTGN) common stock between April 1, 2024 and December 16, 2025. Vistagen Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of therapies for neuropsychiatric and neurological disorders. For more information, submit a form, email attorney Aaron Dumas...

Investor Notice: Robbins LLP Informs Investors of the Securities Class Action Against Oracle Corporation

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP informs investors that a class action was filed on behalf of all persons and/or entities who purchased or otherwise acquired Oracle Corporation (NYSE: ORCL) Senior Notes issued pursuant to the Shelf Registration Statement filed with the SEC on March 15, 2024, and as supplemented on September 25, 2025. Oracle is an Austin, Texas-based company that sells database software, enterprise applications, and cloud infrastructure and hardware. For more information,...

Investor Notice: Robbins LLP Informs Investors of the Smart Digital Group Limited Securities Class Action

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP informs stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Smart Digital Group Limited (NASDAQ: SDM) securities between May 5, 2025 and September 26, 2025. Smart Digital, together with its subsidiaries, provides internet media, business planning and consulting, event planning and execution, and software customization and marketing services in Mainland China and Macau. For more information, submit a fo...
Back to Newsroom